April 17 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR BOTH THE TREATMENT OF MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION (RVO) AND FOR MONTHLY DOSING IN APPROVED INDICATIONS
REGENERON PHARMACEUTICALS INC - FDA TARGET ACTION DATE FOR EYLEA HD SBLA IS AUGUST 19, 2025
Source text: ID:nGNX9kVwHX
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.